A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.

NCT06015048 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

364

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-expressing Advanced Solid Tumors

Interventions

DRUG: SHR-A1811 combined with Pyrotinib.
DRUG: SHR-A1811 combined with other antitumor therapies

Sponsor

Jiangsu HengRui Medicine Co., Ltd.